Researchers sought to determine whether triglyceride levels were independently associated with cardiovascular disease among patients with coronary artery disease and type 2 diabetes.
Evolocumab treatment in addition to statin therapy was found to lower cardiovascular risk in patients with metabolic syndrome and stable atherosclerotic cardiovascular disease.
The 510(k) clearance allows for modification of the labeling of the previously authorized pharmacogenetics report.
Low mean levels and high variability of HDL-C were found to be associated with increased risks for stroke, myocardial infarction and all-cause mortality.
Oral anticoagulation with or without antiplatelet medication was found to increase the risk for bleeding, with minimal protective effect against ischemic stroke in patients with heart failure with reduced ejection fraction and sinus rhythm.
The duration of carotid blood flow reversal during transcarotid artery revascularization for carotid bifurcation stenosis was not found to affect the rate of stroke, myocardial infarction, or death.
There may be an increased risk for ischemic stroke in elderly patients with intracerebral hemorrhage in the first 6 months after diagnosis.
Patients admitted to the hospital for myocardial infarction with a known diagnosis of obstructive sleep apnea were found to have improved in-hospital mortality.
Preexisting mild cognitive impairment (MCI) is associated with a lower use of cardiac catheterization and coronary revascularization after acute myocardial infarction.
A history of migraine in postmenopausal women may not be linked to an increased risk for stroke, myocardial infarction, or composite cardiovascular disease events.
